Guidelines for the standard monitoring of patients with thalassemia: Report of the thalassemia longitudinal cohort

Journal of Pediatric Hematology/Oncology

Volumn 37, Issue 3, 2015, Pages e162-e169

  Tubman, Venée N ^a   Fung, Ellen B ^b   Vogiatzi, Maria ^c   Thompson, Alexis A ^d   Rogers, Zora R ^e   Neufeld, Ellis J ^a   Kwiatkowski, Janet L ^f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

endocrinopathy; iron overload; thalassemia; transfusion; treatment

Indexed keywords

DEFERASIROX; DEFERIPRONE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALLERGIC REACTION; ARTICLE; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION REACTION; BLOODSTREAM INFECTION; BONE DISEASE; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DIABETES MELLITUS; DIARRHEA; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ERYTHROCYTE TRANSFUSION; FEVER; GASTROINTESTINAL SYMPTOM; GENETIC COUNSELING; GROWTH DISORDER; HEART DISEASE; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON OVERLOAD; LIVER INJURY; LONGITUDINAL STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; VOMITING; BLOOD TRANSFUSION; HEMOGLOBINOPATHIES; PHYSIOLOGIC MONITORING; STANDARDS;

BLOOD TRANSFUSION; HEMOGLOBINOPATHIES; HUMANS; LONGITUDINAL STUDIES; MONITORING, PHYSIOLOGIC; THALASSEMIA;

EID: 84926360766     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000307     Document Type: Article

References (68)

1. Weatherall DJ, Williams TN, Allen SJ, et al. The population genetics and dynamics of the thalassemias. Hematol Oncol Clin N Am. 2010;24:1021-1031.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxmine. Haematologia. 2004;89: 1187-1193.
3. Kwiatkowski JL, Kim H-Y, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012;119:2746-2753.
4. Sirchia G, Zanella A, Parravicini A, et al. Red cell alloanti-bodies in thalassemia major. Results of an Italian cooperative study. Transfusion. 1985;25:110-112.
5. Thompson AA, Cunningham MJ, Singer ST, et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol. 2011;153:121-128.
6. Thuret I, Pondarre C, Loundou A, et al. Complications and treatment of patients with b-thalassemia in France: results of the national registry. Haematologica. 2010;95:724-729.
7. Azarkeivan A, Ansari S, Ahmadi MH, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol. 2011;28:479-485.
8. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent tha-lassemia patients of predominantly Asian descent. Blood. 2000;96:3369-3373.
9. Ameen R, Al-shemmari S, Al-humood S, et al. RBC alloimmu-nization and autoimmunization among transfusion-dependent Arab thalassemia patients. Transfusion. 2003;43:1604-1610.
10. Chou ST, Liem RI, Thompson AA. Challenges of alloimmu-nization in patients with haemoglobinopathies. Br J Haematol. 2012;159:394-404.
11. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47.
12. Ladis V, Chouliaras G, Berdoukas V, et al. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86:332-338.
13. Telfer P, Coen PG, Hadjigavriel M, et al. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980-2004. Haematologica. 2006;91: 1187-1192.
14. Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance. J Cardiovasc Mag Res. 2008;10:1-8.
15. Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassae-mia major. Br J Haematol. 2000;110:971-977.
16. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936.
17. Nichols-Vinueza DX, White MT, Powell AJ, et al. MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. Am J Hematol. 2014;89:684-688.
18. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-861.
19. Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2∗ technique for the quantification of tissue iron. Haemato-logica. 2006;91:1388-1391.
20. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460-1465.
21. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-520.
22. Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973-2978.
23. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program. 2011;2011:443-450.
24. Kirk P, Roughton M, Porter JB, et al. Cardiac T2∗ magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-1968.
25. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol. 2009;146:546-556.
26. Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466-475.
27. Bajoria R, Chatterjee R. Hypogonadotrophic hypogonadism and diminished gonadal reserve accounts for dysfunctional gametogenesis in thalassaemia patients with iron overload presenting with infertility. Hemoglobin. 2011;35:636-642.
28. Singer ST, Vichinsky EP, Gildengorin G, et al. Reproductive capacity in iron overloaded women with thalassemia major. Blood. 2011;118:2878-2881.
29. Skordis N, Petrikkos L, Toumba M, et al. Update on fertility in thalassaemia major. Pediatr Endocrinol Rev. 2004;2(suppl 2):296-302.
30. Origa R, Piga A, Quarta G, et al. Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica. 2010;95:376-381.
31. Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87:155-160.
32. Tsapas A, Vlachaki E, Christoforidis A, et al. Insulin sensitivity assessment wih euglycemic insulin clamp in adult beta-thalassae-mia major patients. Eur J Haematol. 2007;79:526-530.
33. Quinn CT, Johnson VL, Kim H-Y, et al. Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153:111-117.
34. Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24:543-557.
35. Fuchs GJ, Tienboon P, Khaled MA, et al. Nutritional support and growth in thalassaemia major. Arch Dis Child. 1997;76:509-512.
36. Soliman AT, El-Matary W, Fattah MMA, et al. The effect of high-calorie diet on nutritional parameters of children with beta-thalassaemia major. Clin Nutr. 2004;23:1153-1158.
37. Fung EB, Xu Y, Kwiatkowski JL, et al. Relationship between chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr. 2010;157:641-647, e2.
38. Fung EB, Xu Y, Trachtenberg F, et al. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet. 2012;112:980-990.
39. Fung EB, Vichinsky EP, Kwiatkowski JL, et al. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone. 2011;48:1305-1312.
40. Trachtenberg F, Foote D, Martin M, et al. Pain as an emergent issue in thalassemia. Am J Hematol. 2010;85:367-370.
41. Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24:1905-1917.
42. Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci. 2005;1054:457-461.
43. Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program. 2011;2011:451-458.
44. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403-409.
45. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. NEJM. 1986;314:869-873.
46. Arden GB, Wonke B, Kennedy C, et al. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68:873-877.
47. De Sanctis V, Pinamonti A, Di Palma A, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Haematol. 1996;155: 368-372.
48. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460-466.
49. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108:305-312.
50. Erdogan E, Canatan D, Ormeci AR, et al. The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol. 2012;27:109-111.
51. O'Brien RT. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann N Y Acad Sci. 1974;232:221-225.
52. Nienhuis AW. Vitamin C and iron. NEJM. 1981;304:170-171.
53. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884-893.
54. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336.
55. al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associ-ated myelotoxicity. Eur J Haematol. 1994;53:298-301.
56. al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995; 91: 224-229.
57. Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:456-462.
58. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev. 2008;22:53-63.
59. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122:1072-1078.
60. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci. 2005;1054:186-195.
61. Cao A, Kan YW. The prevention of thalassemia. Cold Spring Harb Perspect Med. 2013;3:a011775.
62. Borgna-Pignatti C, Gamberini MR. Complications of thalas-semia major and their treatment. Expert Rev Hematol. 2011;4:353-366.
63. Zeinalian M, Nobari RF, Moafi A, et al. Two decades of premarital screening for beta-thalassemia in central Iran. J Community Genet. 2013;4:517-522.
64. Yamashita R, Sobota A, Trachtenberg F, et al. The impact of the child with thalassemia on the family: parental assessment by child health questionnaire. Blood. 2009;114:Abstract 1371.
65. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: a comparison of SF-36 results from the thalasse-mia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011;86:92-95.
66. Payne KA, Desrosiers M-P, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion. 2007;47:1820-1829.
67. Payne KA, Rofail D, Baladi J-F, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25: 725-742.
68. Messina G, Colombo E, Cassinerio E, et al. Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med. 2008;3:339-343.